America First Report
STORY AT-A-GLANCE
- Pfizer announced preliminary data from Phase 2/3 trials in children 6 months to under 5 years would be submitted to the FDA for emergency use authorization; the data are based on 1,678 children and 10 who got sick, which Pfizer claims is an 80.3% effectiveness rate
- Even vaccine advocate Dr. Paul Offit is dismayed at the number from which Pfizer is drawing conclusions. Just days before, New York announced the vaccine efficacy in children 5 to 11 years fell to 12% within two months after vaccination
- Despite 48,833 records in VAERS of adverse events in children under 18 from the vaccine, Pfizer says the shot for 6 months to under 5 years old has “a safety profile similar to placebo”
- Moderna announced their submission to the FDA for children younger than 5 years has a 37% to 51% effectiveness, which is close to the effectiveness of the flu vaccine
- Data from the CDC show that as the months roll by, more Americans are not taking or completing the shots to meet CDC criteria to be fully vaccinated. The push to vaccinate children may likely be related to the pharmaceutical industry’s goal to mandate the vaccine under full legal immunity from damages
May 23, 2022, Pfizer-BioNTech1 announced preliminary results from their Phase 2/3 trial evaluating a three-dose vaccine schedule for children 6 months to under 5 years of age would be submitted to the FDA for emergency use authorization (EUA).
Many in mainstream media are hailing this development as important to children’s health, writing, “many parents of these very young children have been really anxious to get their kids vaccinated”2 and “Parents hoping to get their youngest children vaccinated against COVID-19 got some encouraging news Monday.”3
Yet, despite the continued push by mainstream media to encourage parents to vaccinate the very young, the Vaccine Monitor Survey from KFF4 found only 18% of parents with children under age 5 are planning to get their child vaccinated immediately.
